Wednesday, November 19, 2008

Ceftaroline

Ceftaroline is considered as fifth generation cephalosporin. (George H. Talbot et al.) It is a
metabolite of Ceftaroline fosamil.

Action:
(George H. Talbot et al.) It is much potent in vitro against Methicillin resistant staphylococcus aureus.(Shazad Mushtaq et al) It shows good anti-pneumococcal activity.

Therapeutic Uses:
It is used for different skin infections and those infections which are related to skin structure (2).

Administration:
It is administered parenterally (1).

Adverse effects:
In phase 2 studies, it shows only mild headache (2).

References:
(1) http://www.lifescience-online.com/CEFTAROLINE_ACETATE,8270.html?portalPage=Drugs

(2) http://www.medicalnewstoday.com/articles/53029.php

George H. Talbot, Dirk Thye, Anita Das, and Yigong Ge. Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, October 2007, Volume 51, Number 10, pages 3612-3616.

Shazad Mushtaq, Marina Warner,Yigong Ge, Kone Kaniga, David M Livermore. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Journal of Antimicrobial Chemotherapy. Volume 60 Number 2: Pages 300-311, August 2007.

Further reading:
Natural Compounds as Drugs, Volume I (Progress in Drug Research) (Progress in Drug Research) by Frank Peterson and RenAc Amstutz

Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures (Infectious Disease and Therapy) by Jr. Robert C. Owens and Ebbing Lautenbach

Nosocomial Pneumonia: Strategies for Management by Jordi Rello

Copyright, (c), 2008, http://jeepakistan.blogspot.com

No comments: